Leap Therapeutics (LPTX) Peer Comparison

$1.58

$-0.47 (-22.93%)

As on 11-Dec-2025 09:30EDT

Market cap

$116 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

27.3

Div. Yield

0 %

Edit

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Market cap ($ Mln)	116	4,499	96
Revenue ($ Mln)	0	--	-4
Net Profit ($ Mln)	-98.22	-292.82	-204.39
Net Margin (%)	-22,170.65	-7,320,500.00	5,677.56
RoE (%)	-834.64	-28.69	--
Price to Earnings	--	--	--
Price-To-Book	27.25	4.70	0.93

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Operating Revenue	0.44	0.00	-3.60
Cost of Revenue	31.01	0.00	1.68
Gross Profit	-0.01	-0.02	1.00
Operating Expenses	75.07	330.02	206.85
Operating Profit (EBIT)	-105.64	-330.02	-207.32
Other Income	0.00	0.00	0.00
Profit before Tax	-100.25	-292.82	-204.39
Provision for Tax	-2.30	0.00	-0.09
Profit after Tax (Net Income)	-98.22	-292.82	-204.39
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Shareholder's Funds	2.70	957.64	-55.65
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	0.00	0.29	83.31
Current Liabilities	8.70	47.65	44.75
Total Liabilities	49.12	825.89	179.84

Assets ($ Mln)

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Non-Current Assets	0.90	251.04	43.49
Current Assets	10.50	754.54	28.91
Total Assets	49.12	825.89	179.84
Total Debt*	0.04	1.16	88.94
Net Current Assets	0.00	706.88	-15.84

Cashflow ($ Mln)

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Cash From Operating Activities	-60.30	-230.11	-92.46
Cash Flow from Investing Activities	--	-109.71	-41.89
Cash from Financing Activities	37.18	445.85	120.00
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
ROCE (%)	-141.16	-37.39	-86.23
ROE (%)	-834.64	-28.69	-189.84
ROA (%)	-190.64	-30.60	-107.81
EBIT Margin (%)	-10,576.52	-7,205,162.50	4,048.00
Net Margin (%)	-22,170.65	-7,320,500.00	5,677.56
Cash Profit Margin (%)	--	-488.03	0.00

Growth Ratios

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Revenue Growth (%)	31.45	-98.59	-38.46
EBIT Growth (%)	26.65	-23.77	-24.04
Net Profit Growth (%)	-27.89	-23.44	-88.39
EPS Growth (%)	0.23	-0.06	-97.54
Book Value Growth (%)	-94.53	9.83	-134.32

Valuation Ratios

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Price / Earnings	-1.76	-7.79	-0.74
Price / Book Value	3.38	2.62	1.38
Dividend Yield (%)	--	--	--
EV/EBITDA	-1.02	-5.08	-0.47
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Debt to Equity	0.00	0.00	0.00
Short term debt to equity ratio	0.01	0.00	-0.10
Current Ratio	1.21	15.83	0.65
Quick Ratio	1.21	15.83	0.65
Interest Coverage	-4,357.87	-62.41	--

Operating Efficiency Ratios

	Leap Therapeutics (LPTX)	Akero Therapeutics (AKRO)	Adverum Biotechnologies (ADVM)
Debtors to sales (%)	0.00	0.00	0.00
Asset Turnover	0.01	0.00	-0.02
Receivable days	--	--	--
Inventory Days	--	--	--
Payable days	409,372.20	162,992.81	176.53
Cash Conversion Cycle	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly